WO2000017639A1 - Predictive assay for immune response - Google Patents
Predictive assay for immune response Download PDFInfo
- Publication number
- WO2000017639A1 WO2000017639A1 PCT/US1999/021931 US9921931W WO0017639A1 WO 2000017639 A1 WO2000017639 A1 WO 2000017639A1 US 9921931 W US9921931 W US 9921931W WO 0017639 A1 WO0017639 A1 WO 0017639A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- antigens
- vaccine composition
- antigen presenting
- cell response
- Prior art date
Links
- 238000003556 assay Methods 0.000 title description 13
- 230000028993 immune response Effects 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 164
- 229960005486 vaccine Drugs 0.000 claims abstract description 164
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 140
- 239000000427 antigen Substances 0.000 claims abstract description 139
- 108091007433 antigens Proteins 0.000 claims abstract description 139
- 102000036639 antigens Human genes 0.000 claims abstract description 139
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 76
- 230000005867 T cell response Effects 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 64
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 36
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 36
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 36
- 241001465754 Metazoa Species 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 59
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 108090000695 Cytokines Proteins 0.000 claims description 27
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 15
- 230000009089 cytolysis Effects 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 230000001681 protective effect Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 241000700605 Viruses Species 0.000 description 20
- 238000009472 formulation Methods 0.000 description 17
- 244000052769 pathogen Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000001717 pathogenic effect Effects 0.000 description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 239000012634 fragment Substances 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000700618 Vaccinia virus Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 229940124894 Fluzone Drugs 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 101710205625 Capsid protein p24 Proteins 0.000 description 5
- 241000712431 Influenza A virus Species 0.000 description 5
- 101710177166 Phosphoprotein Proteins 0.000 description 5
- 101710149279 Small delta antigen Proteins 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101710188853 Thioredoxin, mitochondrial Proteins 0.000 description 2
- 102100034795 Thioredoxin, mitochondrial Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100025193 OTU domain-containing protein 4 Human genes 0.000 description 1
- 241000700635 Orf virus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- -1 concentrations Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000047057 human SCGB3A1 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001048 lympholytic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99946995A EP1116026A1 (en) | 1998-09-23 | 1999-09-21 | Predictive assay for immune response |
JP2000571249A JP2002525601A (en) | 1998-09-23 | 1999-09-21 | Predictive assay for immune response |
AU59286/99A AU5928699A (en) | 1998-09-23 | 1999-09-21 | Predictive assay for immune response |
CA002343973A CA2343973A1 (en) | 1998-09-23 | 1999-09-21 | Predictive assay for immune response |
US09/782,709 US6627407B2 (en) | 1998-09-23 | 2001-02-13 | Predictive assay for immune response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/159,172 | 1998-09-23 | ||
US09/159,172 US6962790B1 (en) | 1998-09-23 | 1998-09-23 | Predictive assay for immune response |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/159,172 Continuation US6962790B1 (en) | 1998-09-23 | 1998-09-23 | Predictive assay for immune response |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/782,709 Continuation US6627407B2 (en) | 1998-09-23 | 2001-02-13 | Predictive assay for immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000017639A1 true WO2000017639A1 (en) | 2000-03-30 |
Family
ID=22571391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/021931 WO2000017639A1 (en) | 1998-09-23 | 1999-09-21 | Predictive assay for immune response |
Country Status (6)
Country | Link |
---|---|
US (4) | US6962790B1 (en) |
EP (1) | EP1116026A1 (en) |
JP (1) | JP2002525601A (en) |
AU (1) | AU5928699A (en) |
CA (1) | CA2343973A1 (en) |
WO (1) | WO2000017639A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7387882B2 (en) | 1998-09-23 | 2008-06-17 | University Of Massachusetts Medical Center | Predictive assay for immune response |
AU2004271951B2 (en) * | 2003-09-05 | 2008-08-21 | Genencor International, Inc. | HPV CD8+ T-cell epitopes |
WO2015071763A3 (en) * | 2013-11-15 | 2015-11-26 | Oslo Universitetssykehus Hf | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof |
EP2432893B1 (en) * | 2009-05-19 | 2019-05-01 | University Of Miami | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067535B2 (en) * | 2003-01-24 | 2011-11-29 | The University Of Massachusetts | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
WO2004067032A2 (en) * | 2003-01-24 | 2004-08-12 | University Of Massachusetts Medical Center | Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes |
US20090075304A1 (en) * | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
US20090233318A1 (en) * | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
US9533036B2 (en) * | 2005-11-07 | 2017-01-03 | Microvax, Llc | Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein |
WO2009026547A1 (en) * | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Methods of assaying vaccine potency |
US20100159485A1 (en) * | 2008-12-19 | 2010-06-24 | Centre For Dna Fingerprinting And Diagnostics | Detection of mycobacterium tuberculosis |
CA2778059A1 (en) * | 2009-10-21 | 2011-04-28 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Methods for diagnosis of immune responses against viruses |
WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
SG10201603896RA (en) | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
TWI654302B (en) | 2016-01-19 | 2019-03-21 | 輝瑞股份有限公司 | Cancer vaccine |
CN111065408A (en) | 2017-07-11 | 2020-04-24 | 辉瑞公司 | Immunogenic compositions |
KR102208182B1 (en) * | 2017-09-19 | 2021-01-27 | 서울대학교산학협력단 | Method of Measuring Immunogenicity |
US11435351B2 (en) | 2018-04-18 | 2022-09-06 | Biomadison, Inc. | Methods for determining vaccine potency |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750356A (en) * | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200320A (en) * | 1987-12-07 | 1993-04-06 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying useful polypeptide vaccines |
US5766601A (en) | 1990-08-08 | 1998-06-16 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
WO1994022917A1 (en) | 1993-04-05 | 1994-10-13 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
US5888775A (en) | 1994-04-29 | 1999-03-30 | Dade International Inc | Peptide synthesis and purification by fusion to penI protein or precipitation effective portion thereof |
AU4369596A (en) * | 1994-11-21 | 1996-06-17 | Virginia L. Scofield | Sperm as vaccine vectors |
US6001372A (en) * | 1995-08-25 | 1999-12-14 | Wisconsin Alumni Research Foundation | Antigenic peptides of Chlamydia trachomatis |
US6410252B1 (en) * | 1995-12-22 | 2002-06-25 | Case Western Reserve University | Methods for measuring T cell cytokines |
WO1997035035A1 (en) | 1996-03-20 | 1997-09-25 | Charles Nicolette | A method for identifying cytotoxic t-cell epitopes |
AU738649B2 (en) * | 1996-04-26 | 2001-09-20 | Rijksuniversiteit Te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
US6962790B1 (en) * | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
-
1998
- 1998-09-23 US US09/159,172 patent/US6962790B1/en not_active Expired - Lifetime
-
1999
- 1999-09-21 WO PCT/US1999/021931 patent/WO2000017639A1/en active Application Filing
- 1999-09-21 AU AU59286/99A patent/AU5928699A/en not_active Abandoned
- 1999-09-21 CA CA002343973A patent/CA2343973A1/en not_active Abandoned
- 1999-09-21 JP JP2000571249A patent/JP2002525601A/en active Pending
- 1999-09-21 EP EP99946995A patent/EP1116026A1/en not_active Withdrawn
-
2001
- 2001-02-13 US US09/782,709 patent/US6627407B2/en not_active Expired - Lifetime
-
2005
- 2005-05-13 US US11/129,223 patent/US7387882B2/en not_active Expired - Lifetime
-
2008
- 2008-05-21 US US12/154,287 patent/US20080299603A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750356A (en) * | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
Non-Patent Citations (2)
Title |
---|
LEIN A.D. ET AL.: "In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tubercolosis infection and assessment of response to mycobacterial vaccines", THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol. 313, no. 6, June 1997 (1997-06-01), pages 364 - 371, XP000865852 * |
REITAN L J ET AL: "In vitro methods for vaccine evaluation.", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, (1997) 90 293-301. REF: 24, vol. 90, 1997, pages 293 - 301, XP000865850 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7387882B2 (en) | 1998-09-23 | 2008-06-17 | University Of Massachusetts Medical Center | Predictive assay for immune response |
AU2004271951B2 (en) * | 2003-09-05 | 2008-08-21 | Genencor International, Inc. | HPV CD8+ T-cell epitopes |
EP2432893B1 (en) * | 2009-05-19 | 2019-05-01 | University Of Miami | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
EP3611270A1 (en) * | 2009-05-19 | 2020-02-19 | University Of Miami | Kits for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
WO2015071763A3 (en) * | 2013-11-15 | 2015-11-26 | Oslo Universitetssykehus Hf | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof |
US11452767B2 (en) | 2013-11-15 | 2022-09-27 | Oslo Universitetssykehus Hf | CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU5928699A (en) | 2000-04-10 |
EP1116026A1 (en) | 2001-07-18 |
US7387882B2 (en) | 2008-06-17 |
US6627407B2 (en) | 2003-09-30 |
US6962790B1 (en) | 2005-11-08 |
US20080299603A1 (en) | 2008-12-04 |
US20050277109A1 (en) | 2005-12-15 |
US20010055752A1 (en) | 2001-12-27 |
JP2002525601A (en) | 2002-08-13 |
CA2343973A1 (en) | 2000-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7387882B2 (en) | Predictive assay for immune response | |
Jameson et al. | Human cytotoxic T-lymphocyte repertoire to influenza A viruses | |
Thakur et al. | Immune markers and correlates of protection for vaccine induced immune responses | |
Po et al. | Age-associated decrease in virus-specific CD8+ T lymphocytes during primary influenza infection | |
Miller et al. | Novel lipidated imidazoquinoline TLR7/8 adjuvants elicit influenza-specific Th1 immune responses and protect against heterologous H3N2 influenza challenge in mice | |
Pei et al. | Memory T cells protect chicks from acute infectious bronchitis virus infection | |
AU2007229263B2 (en) | A method for detecting antigen-specific or mitogen-activated T cells | |
Paillot et al. | Protection, systemic IFN $\gamma $, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host | |
JP2000510689A (en) | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating the selected epitopes | |
Effros et al. | Diminished T-cell response to influenza virus in aged mice. | |
Paillot et al. | ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse | |
Tobery et al. | A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay | |
CN102459629B (en) | Composition, kit and method for ex vivo antigen presentation, assessment efficacy of vaccines and assessment biological agent and the immunotoxicity of drug | |
Rojas et al. | T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep | |
Tormo et al. | Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals | |
WO2022023727A1 (en) | Polypeptide panels and uses thereof | |
Rojas et al. | Vaccination with recombinant adenovirus expressing peste des petits ruminants virus-F or-H proteins elicits T cell responses to epitopes that arises during PPRV infection | |
Walker et al. | Longevity of T-cell memory following acute viral infection | |
Aston et al. | Comparison of cellular immune responses to avian influenza virus in two genetically distinct, highly inbred chicken lines | |
Jensen et al. | Early life DNA vaccination with the H gene of Canine distemper virus induces robust protection against distemper | |
Evans et al. | Th1/Th2 cytokine responses following HIV‐1 immunization in seronegative volunteers | |
Rupil et al. | Production of oral vaccines based on virus-like particles pseudotyped with protozoan-surface proteins | |
Anderson et al. | Recognition of respiratory syncytial (RS) virus proteins by human and BALB/c CD4+ lymphocytes | |
Reiss et al. | VSV G protein induces murine cytolytic T lymphocytes | |
El-Sify et al. | Sero-diagnosis of bovine tuberculosis by ELISA using bovine PPD and ST. CF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09782709 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2343973 Country of ref document: CA Ref country code: CA Ref document number: 2343973 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999946995 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 571249 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1999946995 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |